Literature DB >> 19170680

Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clones.

Philip A Beer1, Amy V Jones, Anthony J Bench, Andrea Goday-Fernandez, Elaine M Boyd, Krishna J Vaghela, Wendy N Erber, Bassam Odeh, Christine Wright, Mary Frances McMullin, Jonathan Cullis, Brian J P Huntly, Claire N Harrison, Nicholas C P Cross, Anthony R Green.   

Abstract

This study looked for clonal diversity in patients with a myeloproliferative neoplasm associated with more than one acquired genetic lesion. A tyrosine kinase mutation and a cytogenetic lesion were present in the same clone in six of seven patients. By contrast, the genetic lesions were present in separate clones in all six patients with two tyrosine kinase pathway mutations. Moreover, in two patients the clones were genetically unrelated by X-chromosome inactivation studies. These data demonstrated clonal diversity in a subset of patients with early stage haematopoietic malignancy and showed, for the first time, that such clones may arise independently.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19170680     DOI: 10.1111/j.1365-2141.2008.07560.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  22 in total

Review 1.  Disordered epigenetic regulation in the pathophysiology of myeloproliferative neoplasms.

Authors:  Su-Jiang Zhang; Omar Abdel-Wahab
Journal:  Curr Hematol Malig Rep       Date:  2012-03       Impact factor: 3.952

2.  JAK2-V617F-mutated myeloproliferative neoplasms reveal different allele burden within hematopoietic cell lineages: a microdissection study of bone marrow trephine biopsies.

Authors:  Andreas Kreft; Thomas Kindler; Erik Springer; Charles James Kirkpatrick
Journal:  Virchows Arch       Date:  2011-10-18       Impact factor: 4.064

3.  Molecular basis and clonal evolution of myeloproliferative neoplasms.

Authors:  Roland Jäger; Robert Kralovics
Journal:  Haematologica       Date:  2010-04       Impact factor: 9.941

4.  Acute lymphoblastic leukemia arising in post-polycythemic myelofibrosis: a rare entity.

Authors:  Maro Ohanian; Vasiliki Leventaki; Srdan Verstovsek; Zeev Estrov; Pei Lin; Cameron Yin; Hagop Kantarjian; Yang Huh; Farhad Ravandi
Journal:  Leuk Lymphoma       Date:  2012-03-13

Review 5.  JAK2 and genomic instability in the myeloproliferative neoplasms: a case of the chicken or the egg?

Authors:  Linda M Scott; Vivienne I Rebel
Journal:  Am J Hematol       Date:  2012-05-28       Impact factor: 10.047

Review 6.  Myeloproliferative neoplasms: from origins to outcomes.

Authors:  Jyoti Nangalia; Anthony R Green
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 7.  Role of TET2 and ASXL1 mutations in the pathogenesis of myeloproliferative neoplasms.

Authors:  Omar Abdel-Wahab; Ayalew Tefferi; Ross L Levine
Journal:  Hematol Oncol Clin North Am       Date:  2012-08-21       Impact factor: 3.722

8.  Modest activity of pomalidomide in patients with myelofibrosis and significant anemia.

Authors:  Naval Daver; Aditi Shastri; Tapan Kadia; Alfonso Quintas-Cardama; Elias Jabbour; Marina Konopleva; Susan O'Brien; Sherry Pierce; Lingsha Zhou; Jorge Cortes; Hagop Kantarjian; Srdan Verstovsek
Journal:  Leuk Res       Date:  2013-07-25       Impact factor: 3.156

Review 9.  Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics.

Authors:  Ayalew Tefferi; Radek Skoda; James W Vardiman
Journal:  Nat Rev Clin Oncol       Date:  2009-10-06       Impact factor: 66.675

Review 10.  Janus kinase deregulation in leukemia and lymphoma.

Authors:  Edwin Chen; Louis M Staudt; Anthony R Green
Journal:  Immunity       Date:  2012-04-20       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.